Literature DB >> 1904381

The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease.

K Teahon1, P Smethurst, M Pearson, A J Levi, I Bjarnason.   

Abstract

This study examines whether treatment of acute Crohn's disease with an elemental diet improves intestinal integrity and inflammation as assessed by a 51Cr-labeled ethylenediaminetetraacetatic acid (EDTA) permeability test and the fecal excretion of 111In-labeled autologous leukocytes, respectively. Thirty-four patients with active Crohn's disease completed a 4-week treatment course with an elemental diet. Active disease was characterized by increased intestinal permeability [24-hour urine excretion of orally administered 51Cr-EDTA, 6.4% +/- 0.6% (mean +/- SE); normal, less than 3.0%] and by high fecal excretion of 111In-labeled leukocytes (14.2% +/- 1.1%; normal, less than 1.0%). Twenty-seven (80%) went into clinical remission, usually within a week of starting treatment. After 4 weeks of treatment, there was a significant decrease in both the urine excretion of 51Cr-EDTA (to 3.4% +/- 0.5%; P less than 0.01) and the fecal excretion of 111In (to 5.7% +/- 1.0%; P less than 0.001), indicating that such treatment is not just symptomatic. A framework for the mechanism by which elemental diet works, centering around the importance of the integrity of the intestinal barrier function, is proposed, and also appears to provide a logical explanation for some relapses of the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904381     DOI: 10.1016/0016-5085(91)90463-u

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  42 in total

Review 1.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 2.  Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical.

Authors:  Gary E Wild; Laurie Drozdowski; Carmela Tartaglia; M Tom Clandinin; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 3.  Nutritional therapy for active Crohn's disease.

Authors:  Paul-A Smith
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 4.  New pathophysiological insights and modern treatment of IBD.

Authors:  Matthias A Engel; Markus F Neurath
Journal:  J Gastroenterol       Date:  2010-03-09       Impact factor: 7.527

5.  Elemental diet induces alterations of the gut microbial community in mice.

Authors:  Akira Andoh; Ryo Inoue; Yuki Kawada; So Morishima; Osamu Inatomi; Masashi Ohno; Shigeki Bamba; Atsushi Nishida; Masahiko Kawahara; Yuji Naito
Journal:  J Clin Biochem Nutr       Date:  2019-07-19       Impact factor: 3.114

Review 6.  Intense nutritional support in inflammatory bowel disease.

Authors:  S Wu; R M Craig
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

7.  Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone.

Authors:  D A Gorard; J B Hunt; J J Payne-James; K R Palmer; R G Rees; M L Clark; M J Farthing; J J Misiewicz; D B Silk
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

8.  Experimental colitis in rats induces low-grade endotoxinemia without hepatobiliary abnormalities.

Authors:  H S Brand; M A Maas; A Bosma; R J Van Ketel; P Speelman; R A Chamuleau
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

9.  Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers.

Authors:  S P Colgan; C N Serhan; C A Parkos; C Delp-Archer; J L Madara
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

10.  Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease.

Authors:  J C Mansfield; M H Giaffer; C D Holdsworth
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.